<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Deng Y</submitter><funding>Fundamental Research Funds for the Central Universities</funding><funding>Princess Margaret Cancer Foundation</funding><funding>National Natural Science Foundation of China</funding><pagination>e70215</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12330342</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>44(18-19)</volume><pubmed_abstract>Overall survival has been used as the primary endpoint for many randomized trials that aim to examine whether a new treatment is non-inferior to the standard treatment or placebo control. When a new treatment is indeed non-inferior in terms of survival, it may be important to assess other outcomes including health utility. However, analyzing health utility scores in a secondary analysis may have limited power since the primary objectives of the original study design may not include health utility. To comprehensively consider both survival and health utility, we developed a composite endpoint, HUS (Health Utility-adjusted Survival), which combines both survival and utility. HUS has been shown to be able to increase statistical power and potentially reduce the required sample size compared t</pubmed_abstract><journal>Statistics in medicine</journal><pubmed_title>Health Utility Survival for Randomized Clinical Trials: Extensions and Statistical Properties.</pubmed_title><pmcid>PMC12330342</pmcid><funding_grant_id>12371264</funding_grant_id><funding_grant_id>CXTD14-05</funding_grant_id><funding_grant_id>12171329</funding_grant_id><pubmed_authors>Hao M</pubmed_authors><pubmed_authors>Huang SH</pubmed_authors><pubmed_authors>de Almeida JR</pubmed_authors><pubmed_authors>Xu W</pubmed_authors><pubmed_authors>Deng Y</pubmed_authors><pubmed_authors>Liu G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Health Utility Survival for Randomized Clinical Trials: Extensions and Statistical Properties.</name><description>Overall survival has been used as the primary endpoint for many randomized trials that aim to examine whether a new treatment is non-inferior to the standard treatment or placebo control. When a new treatment is indeed non-inferior in terms of survival, it may be important to assess other outcomes including health utility. However, analyzing health utility scores in a secondary analysis may have limited power since the primary objectives of the original study design may not include health utility. To comprehensively consider both survival and health utility, we developed a composite endpoint, HUS (Health Utility-adjusted Survival), which combines both survival and utility. HUS has been shown to be able to increase statistical power and potentially reduce the required sample size compared t</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Aug</publication><modification>2026-04-13T08:18:18.082Z</modification><creation>2026-04-07T13:29:45.651Z</creation></dates><accession>S-EPMC12330342</accession><cross_references><pubmed>40772764</pubmed><doi>10.1002/sim.70215</doi></cross_references></HashMap>